中恒集团：纳米炭铁混悬注射液获临床试验批准

Core Viewpoint - Zhongheng Group has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" in combination with standard radiotherapy for solid tumor patients [1] Group 1: Drug Development - The drug utilizes Fe²⁺ as the active anti-cancer ingredient and nano carbon as a carrier, targeting the regulation of ferroptosis pathways to exert anti-cancer effects [1] - The second phase of clinical trials for the drug is progressing smoothly, with some patient enrollments completed [1] - There are currently no similar products on the market or in late-stage research [1] Group 2: Financial Investment - As of the announcement date, Sichuan Yingrui Pharmaceutical Technology Co., Ltd. has invested a total of 94.2826 million RMB (approximately 14.3 million USD) in the research and development of this drug [1]